Studio Promotore Data Parere Unico CE Documenti
Hydroxychloroquine sulfate early administration in symptomatic
out of hospital COVID-19 positive patients (Hydro-Stop-COVID19
Trial)
ASUR-AV5 Ascoli Piceno 08/04/2020
https://www.aifa.gov.it/documents/20142/1131319/H
ydro-Stop_Documenti.zip
A randomized, double-blind, placebocontrolled, multicenter
study to evaluate the safety and efficacy of tocilizumab in
patients with severe covid-19 pneumonia (Tocilizumab 2020-
001154-22 ).
F. Hoffmann-La Roche Ltd 30/03/3020
https://www.aifa.gov.it/documents/20142/1131319/T
ocilizumab_Documenti.zip
Uno studio randomizzato multicentrico in aperto per valutare
l’efficacia della somministrazione precoce del Tocilizumab (TCZ)
in pazienti affetti da polmonite da COVID-19 (RCT-TCZ-COVID-
19).
Azienda Unità Sanitaria Locale-
IRCCS di Reggio Emilia
27/03/2020
https://www.aifa.gov.it/documents/20142/1131319/R
CT-TCZ-COVID19_documenti.zip
An adaptive phase 2/3, randomized, double-blind,
placebocontrolled study assessing efficacy and safety of
sarilumab for hospitalized patients with COVID-19 (Sarilumab
COVID-19).
sanofi-aventis Recherche &
Développement
26/03/2020
https://www.aifa.gov.it/documents/20142/1131319/S
arilumab_documenti.zip
A phase 2/3, randomized, open-label, parallel group, 3-arm,
multicenter study investigating the efficacy and safety of
intravenous administrations of emapalumab, an anti-interferon
gamma (anti-IFNγ) monoclonal antibody, and anakinra, an
interleukin-1(IL-1) receptor antagonist, versus standard of care,
in reducing hyper-inflammation and respiratory distress in
patients with SARSCoV-2 infection (Sobi.IMMUNO-101).
SOBI 25/03/2020
https://www.aifa.gov.it/documents/20142/1131319/S
obi.IMMUNO-101_documenti.zip
Multicenter study on the efficacy and tolerability of tocilizumab
in the treatment of patients with COVID-19 pneumonia (TOCIVID-
19).
Istituto Nazionale Tumori,
IRCCS, Fondazione G. Pascale –
Via M. Semmola 80131 Napoli
22/03/2020
https://www.aifa.gov.it/documents/20142/1131319/T
OCIVID-19_documenti.zip
A Phase 3 Randomized Study to Evaluate the Safety and Antiviral
Activity of Remdesivir (GS-5734™) in Participants with Moderate
COVID-19 Compared to Standard of Care Treatment. (GS-US-540-
5774 Study)
Gilead Sciences, Inc 11/03/2020
https://www.aifa.gov.it/documents/20142/1131319/G
S-US-540-5774_documenti.zip
A Phase 3 Randomized Study to Evaluate the Safety and Antiviral
Activity of Remdesivir (GS-5734™) in Participants with Severe
COVID-19. (GS-US-540-5773 Study)
Gilead Sciences, Inc 11/03/2020
https://www.aifa.gov.it/documents/20142/1131319/G
S-US-540-5773_documenti.zip
